BR0309343A - Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas - Google Patents

Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas

Info

Publication number
BR0309343A
BR0309343A BR0309343-3A BR0309343A BR0309343A BR 0309343 A BR0309343 A BR 0309343A BR 0309343 A BR0309343 A BR 0309343A BR 0309343 A BR0309343 A BR 0309343A
Authority
BR
Brazil
Prior art keywords
compound
prophylaxis
treating
conditions
pharmaceutical composition
Prior art date
Application number
BR0309343-3A
Other languages
English (en)
Inventor
Hui-Fang Chang
Yan Li
Eifion Phillips
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201186A external-priority patent/SE0201186D0/xx
Priority claimed from SE0203607A external-priority patent/SE0203607D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0309343A publication Critical patent/BR0309343A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, MéTODO DE TRATAMENTO OU PROFILAXIA DE DOENçAS OU CONDIçõES HUMANAS". Compostos da fórmula (I) e sais farmaceuticamente aceitáveis dos mesmos, em que Ar e R são como definidos na especificação, composições contendo tais compostos e o uso de tais compostos e composições para o uso em terapia.
BR0309343-3A 2002-04-18 2003-04-15 Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas BR0309343A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0201186A SE0201186D0 (sv) 2002-04-18 2002-04-18 Furyl compounds
SE0203607A SE0203607D0 (sv) 2002-12-04 2002-12-04 Furyl compounds
PCT/SE2003/000613 WO2003087102A1 (en) 2002-04-18 2003-04-15 Furyl compounds

Publications (1)

Publication Number Publication Date
BR0309343A true BR0309343A (pt) 2005-02-15

Family

ID=29253788

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309343-3A BR0309343A (pt) 2002-04-18 2003-04-15 Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas

Country Status (16)

Country Link
US (1) US7417049B2 (pt)
EP (1) EP1499618B1 (pt)
JP (1) JP4511195B2 (pt)
KR (1) KR20040099447A (pt)
CN (1) CN1325500C (pt)
AT (1) ATE484508T1 (pt)
AU (1) AU2003225456B2 (pt)
BR (1) BR0309343A (pt)
CA (1) CA2482311C (pt)
DE (1) DE60334536D1 (pt)
HK (1) HK1079519A1 (pt)
IL (1) IL164509A0 (pt)
MX (1) MXPA04010191A (pt)
NO (1) NO20044996L (pt)
NZ (1) NZ561794A (pt)
WO (1) WO2003087102A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
PL369895A1 (en) 2001-10-02 2005-05-02 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
AU2003224545B2 (en) * 2002-04-18 2009-08-13 Astrazeneca Ab Thienyl compounds
KR20060094962A (ko) 2003-10-21 2006-08-30 아스트라제네카 아베 스피로푸로피리딘 아릴 유도체
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
KR20110019781A (ko) 2008-06-20 2011-02-28 아스트라제네카 아베 디벤조티아제핀 유도체 및 그의 용도
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
MX2012013345A (es) 2010-05-17 2013-02-11 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
BR112012030004A2 (pt) 2010-05-27 2016-08-02 Targacept Inc antagonistas não competitivos de receptor nicotínico
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
EP2953940B1 (en) 2013-02-07 2018-08-22 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic m4 receptor agonists
EA029430B1 (ru) 2013-06-21 2018-03-30 Такеда Фармасьютикл Компани Лимитед Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
EP3215512A1 (en) 2014-11-04 2017-09-13 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
CN108018049B (zh) * 2016-10-28 2019-09-27 西安近代化学研究所 具有5,6-二氟取代苯并呋喃环的液晶化合物
CN108003895B (zh) * 2016-10-28 2019-04-19 西安近代化学研究所 一种向列相液晶组合物及其显示元件
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
EP3790876A1 (en) 2018-05-10 2021-03-17 Zoetis Services LLC Endoparasitic depsipeptides
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
IL158735A0 (en) 2001-06-01 2004-05-12 Astrazeneca Ab Novel ligand for nicotinic acetylcholine receptors useful in therapy
AU2003224545B2 (en) * 2002-04-18 2009-08-13 Astrazeneca Ab Thienyl compounds

Also Published As

Publication number Publication date
EP1499618A1 (en) 2005-01-26
AU2003225456A1 (en) 2003-10-27
WO2003087102A1 (en) 2003-10-23
CA2482311A1 (en) 2003-10-23
NZ561794A (en) 2008-11-28
MXPA04010191A (es) 2005-02-03
US7417049B2 (en) 2008-08-26
JP2005533012A (ja) 2005-11-04
DE60334536D1 (de) 2010-11-25
HK1079519A1 (en) 2006-04-07
AU2003225456B2 (en) 2009-02-05
KR20040099447A (ko) 2004-11-26
JP4511195B2 (ja) 2010-07-28
US20050176745A1 (en) 2005-08-11
CN1662541A (zh) 2005-08-31
IL164509A0 (en) 2005-12-18
CN1325500C (zh) 2007-07-11
CA2482311C (en) 2009-12-08
EP1499618B1 (en) 2010-10-13
ATE484508T1 (de) 2010-10-15
NO20044996L (no) 2005-01-18

Similar Documents

Publication Publication Date Title
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0313234A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto
NO20044995L (no) Heterosykliske forbindelser
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
SE0101387D0 (sv) Novel compounds
BR0313233A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, e, composição farmacêutica
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
GB0112348D0 (en) Compounds
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
DK1483251T3 (da) C3-cyano-epothilon-derivater
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
NO20063619L (no) Diarylmetylpiperazinderivater, fremstilling og anvendelse derav
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
MXPA04005809A (es) Inhibidores de proteinas quinasas.
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
SE0102057D0 (sv) New Salts I
SE0102058D0 (sv) New Salts II
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
DE60309926D1 (de) Steroid-verbindungen mit anti-tumoraler wirkung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 8A E 9A ANUIDADES.